Petrelintide (ZP8396) Dosing Protocol: Long-Acting Amylin Guide
Also known as: ZP8396, Zealand/Roche Neutral-pH Long-Acting Amylin Analog
Studied in published research — not a medical recommendation. Primary protocol (Phase 1b 16-Week Once-Weekly Escalation Protocol): 0.6 mg → 1.2 mg → 2.4 mg → 4.8 mg (or up to 9.0 mg) weekly, Once weekly.
Once weekly
Research-reported range; the linked study used a different dose or units. Achieved 8.6% mean body weight reduction in 16 weeks with minimal GI nausea and zero discontinuations due to GI adverse events in key cohorts
Subcutaneous injection
Human clinical trials or FDA-approved formulation exists
No verified human half-life on file for this compound
A vial is powder until you add bacteriostatic water. Change the vial size or water volume below to see the exact unit mark on your syringe.
All U-100: 100 units = 1 mL. 8 doses in the vial at the low end (4 doses at the high end).
Save Petrelintide to your personal protocol list to log your custom dosage, syringe units, ON/OFF cycle dates, and lab notes across devices.
At a Glance · 2026 FDA / 503A / WADA / Evidence Profile
What is a GLP-1 Agonist?
A molecule that mimics glucagon-like peptide-1 (GLP-1), a hormone that regulates blood sugar, slows gastric emptying, and reduces appetite. Semaglutide (Wegovy/Ozempic) and tirzepatide (Mounjaro/Zepbound) are GLP-1 agonists. These are peptides, but they are marketed and prescribed as pharmaceutical drugs.
Bottom Line Up Front
Petrelintide (ZP8396) is a long-acting acylated amylin analog (Zealand Pharma / Roche) stable at neutral pH (~7.0). Phase 1b trials showed 8.6% weight loss in 16 weeks with minimal GI nausea and high lean mass preservation.
Low-nausea hedonic satiety, lean mass retention, and neutral-pH co-formulation with GLP-1 agonists
High-magnitude standalone glycemic lowering in severe diabetes
ZP8396 (Zealand Pharma / Roche — Phase 2b ZUPREME)
3 (1 human)
EDUCATIONAL AND RESEARCH REFERENCE ONLY — NOT MEDICAL ADVICE. Petrelintide is not FDA approved for human use (unless specified above). This information does not constitute medical advice.
Overview
Amylin is a 37-amino-acid neuroendocrine hormone co-secreted with insulin from pancreatic beta cells that signals fullness via the hindbrain area postrema without triggering the aversive nausea pathways common to high-dose GLP-1 receptor agonists. Petrelintide (ZP8396) is an acylated salmon-calcitonin/human-amylin hybrid peptide with a ~10-day half-life and neutral-pH solubility. In Phase 1b human trials, 16 weeks of weekly Petrelintide produced up to 8.6% mean weight loss with zero severe GI events and high lean-mass retention.
Mechanisms of Action
- Potently activates Amylin receptors (AMY1R, AMY3R) and Calcitonin receptors (CTR) in the area postrema and nucleus tractus solitarii (NTS)
- Restores leptin sensitivity and central hedonic satiety without relying on vagal GLP-1 nausea signaling
- Engineered for chemical stability at physiological neutral pH (pH ~7.0), avoiding the fibril-formation risk of native amylin and acidic pH requirement of cagrilintide
- Suppresses inappropriate postprandial glucagon spikes and slows early gastric emptying
Research Protocols
Summaries of published research. For educational purposes only.
Metabolic, Hepatic & Incretin Safety Biomarker Panel (Petrelintide)
Quantify visceral fat mobilization, insulin resistance reversal, hepatic steatosis (MASH) clearance, and pancreatic/renal safety during metabolic protocols.
HbA1c & Fasting Insulin (HOMA-IR)
Day 0 + Wk 6–8Why track at baseline: Measures baseline hyperinsulinemia and 90-day glycemic load prior to incretin or lipolytic initiation.
Week 6–8 check: Track rapid drop in Fasting Insulin (often 30%–50% reduction by Week 6–8) and normalizing HbA1c.
ALT, AST & GGT Liver Enzymes
Day 0 + Wk 6–8Why track at baseline: Dual/triple agonists (Retatrutide, Mazdutide, Pemvidutide) mobilize 65%–80% of intrahepatic triglycerides.
Week 6–8 check: Confirm progressive reduction in ALT/AST (<25 U/L) as hepatic steatosis clears.
ApoB, Triglycerides & Advanced Lipid Panel
Day 0 + Wk 6–8Why track at baseline: Quantifies atherogenic particle burden and VLDL triglyceride export before weight loss.
Week 6–8 check: Expect 20%–40% triglyceride drop and significant ApoB improvement alongside visceral fat loss.
Serum Lipase, Amylase & eGFR / Cystatin C
Day 0 + Wk 6–8Why track at baseline: Essential safety screen for subclinical pancreatic inflammation and hydration/renal filtration.
Week 6–8 check: Ensure Lipase stays within reference range and eGFR remains stable with adequate electrolyte hydration.
Related Studies
16-week randomized double-blind Phase 1b trial showed dose-dependent weight loss up to 8.6% with a benign GI tolerability profile compared with GLP-1 receptor agonists.
Limitations: Larger Phase 2b trials (ZUPREME-1 and ZUPREME-2) currently underway.
Community Outcomes
Community Data Coming Soon
Aggregate community outcomes will be displayed here once we have more reports. Be one of the first to share your experience!
Outcomes are self-reported and unverified. They represent individual experiences and may not reflect typical results.
Important Warnings
- •Currently in Phase 2b clinical trials (ZUPREME-1/2) — not yet FDA approved
- •Monitor fasting glucose and GI motility if stacked with a GLP-1/GIP agonist
- •Verify neutral buffered reconstitution pH if handling lyophilized research standards
Where to get Petrelintide, baseline labs & clinician oversight.
Ascension Peptides (US Vials)
MZ Biolabs & SafeCert COA-verified US domestic single vials with 50% off auto-applied for new customers.
SwissChems & Limitless Biotech
Same-day US domestic lyophilized vials, oral capsules, and endotoxin-screened nasal sprays (15% off Limitless w/ code PEPTIDEPROTOCOLS).
Superpower Labs & 503A Telehealth
Bloodwork, not a vial store. Get a baseline panel (100+ Quest biomarkers: metabolic, lipids, hormones, inflammation, kidney/liver) before you start a peptide protocol, then retest mid-cycle to see what actually changed.
Peptide Reconstitution & U-100 Syringe Cheat Sheet
Printable U-100 insulin syringe draw chart for 5mg–50mg vials, plus our weekly $/mg price-drop brief.
Related Peptides
More metabolic peptides
Semaglutide
Semaglutide is a GLP-1 receptor agonist that mimics the horm...
Tirzepatide
Tirzepatide is a dual GIP and GLP-1 receptor agonist. It rep...
Retatrutide
Retatrutide is a triple hormone receptor agonist developed b...
Liraglutide
Liraglutide is an FDA-approved GLP-1 receptor agonist used f...
AOD-9604 (hGH Frag 176-191)
AOD-9604 is a modified fragment of human growth hormone (hGH...
Vendor vs vendor: price per mg
Head-to-head $/mg on shared compounds. Prices verified Nov 11, 2026.
- Ascension vs SwissChems (3 shared compounds)
- Elite vs SwissChems (3 shared compounds)
- Elite vs Ascension (26 shared compounds)
- Protide vs SwissChems (3 shared compounds)
- Protide vs Ascension (6 shared compounds)
- Ameano vs SwissChems (3 shared compounds)
- Ameano vs Ascension (4 shared compounds)
- Swift vs Ascension (23 shared compounds)
- BioLongevity vs Ascension (16 shared compounds)
- Peptyes vs SwissChems (3 shared compounds)
- Peptyes vs Elite (20 shared compounds)
- Peptyes vs Swift (17 shared compounds)
- Peptyes vs Pure (17 shared compounds)
- Peptyes vs Ascension (20 shared compounds)
Compound vs compound: BPC-157 vs TB-500 · Tirzepatide vs Semaglutide · Retatrutide vs Tirzepatide · Wolverine Blend vs GLOW Blend · Semax vs Selank · KLOW Blend vs GLOW Blend · MOTS-c vs SS-31 · Sermorelin vs Ipamorelin · Retatrutide vs Semaglutide · Tesamorelin vs Sermorelin · All compounds $/mg →
Common questions
How many peptides are in the database?
100 compound pages, each with dosing references, reconstitution math and price per mg where a verified vendor price exists.
Where can I compare peptide prices?
Each compound page shows verified $/mg by vendor; the vendor-vs-vendor pages above compare two vendors across their shared compounds.